Chardan analyst Matthew Barcus initiated coverage of Applied Molecular Transport with a Buy rating and $3 price target. Applied I is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune, inflammatory, and metabolic diseases, Barcus tells investors in a research note. The analyst says the company is addressing rheumatoid arthritis with AMTI‘s IL-10 fusion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMTI:
- Applied Molecular Transport announces FDA ODD granted to AMT-101
- Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
- Applied Molecular Transport to Present at Upcoming November Investor Conferences
- Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update